I. Maclachlan

发表

RNAi-mediated gene silencing in non-human primates

Matthias John, Akin Akinc, M. Manoharan, 2006, Nature.

Progress towards a synthetic virus for systemic gene therapy.

I. Maclachlan, P. Cullis, R. Graham, 1999, Current opinion in molecular therapeutics.

Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA.

J. Heyes, L. Jeffs, L. Palmer, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

13 Synthetic Virus Systems for Systemic Gene Therapy

I. Maclachlan, P. Cullis, R. Graham, 2000 .

Liposomal Formulations for Nucleic Acid Delivery

I. Maclachlan, 2007 .

Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery.

J. Heyes, I. Maclachlan, K. Hall, 2006, Journal of controlled release : official journal of the Controlled Release Society.

Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids.

J. Heyes, L. Palmer, I. Maclachlan, 2005, Journal of controlled release : official journal of the Controlled Release Society.

A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA

L. Jeffs, L. Palmer, I. Maclachlan, 2005, Pharmaceutical Research.

Cationic lipid-mediated transfection of cells in culture requires mitotic activity

I. Maclachlan, R. Graham, P. Joshi, 1999, Gene Therapy.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Keith Bowman, B. Polisky, L. Jeffs, 2005, Nature Biotechnology.

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

A. Judge, K. Mcclintock, Vandana Sood, 2005, Nature Biotechnology.

Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.

A. Lee, A. Judge, I. Maclachlan, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Stabilized plasmid-lipid particles: construction and characterization

L. Palmer, I. Maclachlan, P. Cullis, 1999, Gene Therapy.

Rational design of cationic lipids for siRNA delivery

K. G. Rajeev, M. Manoharan, A. Akinc, 2010, Nature Biotechnology.

siRNA and innate immunity.

A. Judge, I. Maclachlan, M. Robbins, 2009, Oligonucleotides.

Factors limiting autogene‐based cytoplasmic expression systems

I. Maclachlan, P. Cullis, J. Finn, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Stabilized plasmid-lipid particles: a systemic gene therapy vector.

I. Maclachlan, P. Cullis, D. Fenske, 2002, Methods in enzymology.

Long-circulating vectors for the systemic delivery of genes.

I. Maclachlan, P. Cullis, D. Fenske, 2001, Current opinion in molecular therapeutics.

Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA

I. Maclachlan, C. Mire, M. Robbins, 2014, Science Translational Medicine.

Therapeutic Target in Human Hepatocellular Carcinoma Definition of Ubiquitination Modulator COP 1 as a Novel

S. Thorgeirsson, H. Woo, V. Factor, 2010 .

inition of Ubiquitination Modulator COP 1 as a Novel R rapeutic Target in Human Hepatocellular Carcinoma

S. Thorgeirsson, H. Woo, V. Factor, 2010 .

Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice

C. Contag, R. Spitler, A. Judge, 2013, Molecular therapy. Nucleic acids.

Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.

I. Maclachlan, A. Dallas, Joshua Shorenstein, 2014, Gastroenterology.

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease

A. Lee, I. Maclachlan, C. Mire, 2017, The Journal of clinical investigation.

Inhibition of Hepatitis C Virus in Chimeric Mice by Short Synthetic Hairpin RNAs: Sequence Analysis of Surviving Virus Shows Added Selective Pressure of Combination Therapy

I. Maclachlan, D. Chin, A. Dallas, 2014, Journal of Virology.

Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids.

T. Chen, L. Palmer, I. Maclachlan, 2003, Biochimica et biophysica acta.

Riboflavinuria in the rd chicken. 5'-splice site mutation in the gene for riboflavin-binding protein.

I. Maclachlan, W. Schneider, J. Nimpf, 1993, The Journal of biological chemistry.

siRNAs with guts

I. Maclachlan, 2008, Nature Biotechnology.

Protection Against Lethal Marburg Virus Infection Mediated by Lipid Encapsulated Small Interfering RNA

A. Judge, I. Maclachlan, C. Mire, 2013, The Journal of infectious diseases.

analysis of surviving virus shows added selective pressure of combination

I. Maclachlan, D. Chin, A. Dallas, 2014 .

Abstract 2829: Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1

A. Judge, K. Mcclintock, I. Maclachlan, 2011 .

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.

A. Judge, K. Mcclintock, I. Maclachlan, 2009, The Journal of clinical investigation.

Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

A. Judge, K. Mcclintock, I. Maclachlan, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression.

J. Heyes, L. Palmer, I. Maclachlan, 2005, Biochimica et biophysica acta.

2'-O-methyl-modified RNAs act as TLR7 antagonists.

A. Judge, K. Mcclintock, Ed Yaworski, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference

P. Jahrling, L. Jeffs, A. Judge, 2006, The Journal of infectious diseases.

Silençage de l'expression de la polo-like kinase à l'aide d'un arn interférent

A. Judge, I. Maclachlan, 2008 .

Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.

S. Thorgeirsson, V. Factor, A. Judge, 2014, Cancer Research.

582. Synthetic siRNA Can Activate the Mammalian Innate Immune Response in a Sequence Dependent Manner

A. Judge, K. Mcclintock, Vandana Sood, 2005 .

An enhanced autogene-based dual-promoter cytoplasmic expression system yields increased gene expression

I. Maclachlan, P. Cullis, J. Finn, 2004, Gene Therapy.

Lipoprotein Receptor-Mediated Oocyte Growth

I. Maclachlan, W. Schneider, A. Vieira, 1993 .

Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation.

A. Judge, K. Mcclintock, L. Palmer, 2008, Human gene therapy.

Misinterpreting the therapeutic effects of siRNA caused by immune stimulation

A. Judge, K. Mcclintock, L. Palmer, 2008 .

Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response

S. Thorgeirsson, V. Factor, S. Thorgeirsson, 2011, Oncogene.

Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma.

S. Thorgeirsson, H. Woo, V. Factor, 2010, Cancer research.

Molecular characterization of quail apolipoprotein very-low-density lipoprotein II: disulphide-bond-mediated dimerization is not essential for inhibition of lipoprotein lipase.

I. Maclachlan, W. Schneider, J. Nimpf, 1996, The Biochemical journal.

Characterization of the Japanese quail oocyte receptor for very low density lipoprotein and vitellogenin.

I. Maclachlan, W. Schneider, R. G. Elkin, 1995, The Journal of nutrition.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study

Joshua C. Johnson, A. Judge, Vandana Sood, 2010, The Lancet.

Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates

N. Snead, I. Maclachlan, C. Mire, 2015, Nature.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

I. Maclachlan, C. Mire, M. Robbins, 2016, Nature Microbiology.

Interferon, Cytokine Induction, and other Potential In Vivo Toxicities

A. Judge, I. Maclachlan, M. Robbins, 2010 .

Overcoming the innate immune response to small interfering RNA.

A. Judge, I. Maclachlan, 2008, Human gene therapy.

"Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles"

I. Maclachlan, P. Cullis, Pieter Cullis, 2005, Advances in genetics.

Analysis of differential lipofection efficiency in primary and established myoblasts.

G. Lukács, I. Maclachlan, L. Vitiello, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition.

M. Borad, A. Judge, I. Maclachlan, 2013 .

Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors.

M. Gilbert, M. Borad, A. Judge, 2013 .

Distinct domains of IkappaB-alpha inhibit human immunodeficiency virus type 1 replication through NF-kappaB and Rev

G. Nabel, I. Maclachlan, C. Woffendin, 1997, Journal of virology.

Abstract 4064: Development of ALN-VSP: An RNAi therapeutic for solid tumors

D. Bumcrot, A. Akinc, T. Racie, 2010 .